MedTrace Logo

A Human Experimental Model for Neuropathic Pain Using Combined Application of Capsaicin and Local Anesthetics

NCT01540877 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2012-02-29

No results posted yet for this study

Summary

Main of the present study was to develop a model of concomitant C-fibre block and sensitization eliciting spontaneous pain as well applying topical capsaicin and local anesthetics (LA) to examine the sensory alterations after combined C-fiber block and sensitization in both different application orders (sensitization of blocked C-fibers and block of sensitized C-fibers), compared to each of both mechanisms alone. Thereby, we expect stronger sensory changes during the combined substance application than during the monoapplication. We expect also contralateral sensory alterations mirroring the changes on the intervention site after the combined capsaicin and LA application, being stronger than after sensitization alone absent after C-fiber block alone.

Conditions

  • Ipsi- and Contralateral Hypoesthesia

Interventions

PROCEDURE

Application of capsaicin 0.6%

topical application of 0.6% capsaicin on the volar forearm

PROCEDURE

Application of local anesthetics (EMLA plaster)

topical application of EMLA on the volar forearm

PROCEDURE

Application of 1 capsaicin 0.6% and 2. EMLA

topical application of 1. 0.6% capsaicin and 2. EMLA on the volar forearm

PROCEDURE

Application of 1. EMLA and 2. capsaicin 0.6%

topical application of 1. EMLA and 2. 0.6% capsaicin on the volar forearm

Sponsors & Collaborators

  • Ruhr University of Bochum

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01540877 on ClinicalTrials.gov